Need support?

Please leave a message

×

Curiox - Laminar Wash Mini System

THAILAND

Somchai Chakornsiri, General Manager

+66 2 639 7000
Contact Email
DKSH Technology Limited (Head Office)
2533 Sukhumvit Road, Bangchak, Phrakhanong
10260 Bangkok
Thailand

NEW ZEALAND

Benoit Fissot, General Manager, Technology, Australia & New Zealand

0800 951 010
Contact Email
DKSH New Zealand Limited
72 Apollo Drive
0632 Mairangi Bay, Auckland
New Zealand

SINGAPORE

Monica Wan, General Manager

+65 6962 3121
Fax +65 6273 1503
Contact Email
DKSH Singapore Pte Ltd
625 Lorong 4 Toa Payoh, #03-00
319519 Singapore
Singapore
  • Laminar Wash Mini System Brochure - Curiox - Protected
    (PDF, 715 KB)

Avoid the centrifuge and improve data quality and biosafety with the Laminar Wash MINI System

The Laminar Wash MINI System employs the only suspension-cell sample preparation method that eliminates the centrifuge and the problems it introduces. It is an affordable bench-top instrument designed to produce the most quantitative and reproducible results for single cell sequencing, flow cytometry and mass cytometry.

What the Mini delivers:

  • Upgrade from the centrifuge — centrifuge-free, laminar flow based washing system
  • Enhance cell retention
  • Reduce hands on time
  • Improve cell viability and reduce stress on cells

Data using the laminar wash system

  • Enhanced Cell Recovery post cell sorting for lower cell numbers
  • Cell-hashing data reveals increased singlet and reduced doublet counts
  • Flexible and optimized performance for using Cite-seq higher antibody panels

Applications

  • Flow cytometry
  • Single cell sequencing
  • Tumor microenvironment
  • COVID-19 sample preparation

Technical Specifications

Voltage Requirements 100-240V
Power Consumption 24V/3.0A
W x H x D (mm) 275 x 232 x 187.5
Weight 3.5kg (7.7 lbs)

See How the Laminar Wash Technology Works

MINI Virtual Demo

  • Biopharmaceutical and Biotechnology
Curiox Biosystems

Curiox was founded in 2008 to commercialize DropArray™ technology, which was initially developed by Namyong Kim, PhD and his group at the Institute of Bioengineering and Nanotechnology (IBN), a part of A*STAR. The venture was backed by Nanostart AG and Exploit Technologies, the commercialization arm of A*STAR.

We look forward to ushering in the next generation of innovations that accelerate the pace of life science research, diagnostics, and therapeutics discovery and development.

[]

Select a market